Original Research
15 October 2019

Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome: A Randomized Noninferiority Trial

Publication: Annals of Internal Medicine
Volume 171, Number 10
Visual Abstract. Rivaroxaban in Antiphospholipid Syndrome Long-term anticoagulation with vitamin K antagonists (VKAs) is the standard of care for preventing thrombosis in patients with antiphospholipid antibody syndrome (APS), but VKAs require frequent monitoring and are associated with food and drug interactions. This 3-year randomized controlled trial compared the efficacy and safety of a newer oral anticoagulant versus dose-adjusted VKAs in patients with APS.
Visual Abstract. Rivaroxaban in Antiphospholipid Syndrome
Long-term anticoagulation with vitamin K antagonists (VKAs) is the standard of care for preventing thrombosis in patients with antiphospholipid antibody syndrome (APS), but VKAs require frequent monitoring and are associated with food and drug interactions. This 3-year randomized controlled trial compared the efficacy and safety of a newer oral anticoagulant versus dose-adjusted VKAs in patients with APS.

Abstract

Background:

The potential role of new oral anticoagulants in antiphospholipid antibody syndrome (APS) remains uncertain.

Objective:

To determine whether rivaroxaban is noninferior to dose-adjusted vitamin K antagonists (VKAs) for thrombotic APS.

Design:

3-year, open-label, randomized noninferiority trial. (EU Clinical Trials Register: EUDRA [European Union Drug Regulatory Authorities] code 2010-019764-36)

Setting:

6 university hospitals in Spain.

Participants:

190 adults (aged 18 to 75 years) with thrombotic APS.

Intervention:

Rivaroxaban (20 mg/d or 15 mg/d, according to renal function) versus dose-adjusted VKAs (target international normalized ratio, 2.0 to 3.0, or 3.1 to 4.0 in patients with a history of recurrent thrombosis).

Measurements:

The primary efficacy outcome was the proportion of patients with new thrombotic events; the primary safety outcome was major bleeding. The prespecified noninferiority margin for risk ratio (RR) was 1.40. Secondary outcomes included time to thrombosis, type of thrombosis, changes in biomarker levels, cardiovascular death, and nonmajor bleeding.

Results:

After 3 years of follow-up, recurrent thrombosis occurred in 11 patients (11.6%) in the rivaroxaban group and 6 (6.3%) in the VKA group (RR in the rivaroxaban group, 1.83 [95% CI, 0.71 to 4.76]). Stroke occurred more commonly in patients receiving rivaroxaban (9 events) than in those receiving VKAs (0 events) (corrected RR, 19.00 [CI, 1.12 to 321.9]). Major bleeding occurred in 6 patients (6.3%) in the rivaroxaban group and 7 (7.4%) in the VKA group (RR, 0.86 [CI, 0.30 to 2.46]). Post hoc analysis suggested an increased risk for recurrent thrombosis in rivaroxaban-treated patients with previous arterial thrombosis, livedo racemosa, or APS-related cardiac valvular disease.

Limitation:

Anticoagulation intensity was not measured in the rivaroxaban group.

Conclusion:

Rivaroxaban did not show noninferiority to dose-adjusted VKAs for thrombotic APS and, in fact, showed a non–statistically significant near doubling of the risk for recurrent thrombosis.

Primary Funding Source:

Bayer Hispania.

Get full access to this article

View all available purchase options and get full access to this article.

Supplemental Material

Supplement. Study Protocol (Supplement 1) and Supplemental Appendices (Supplement 2)

References

1.
Schreiber KSciascia Sde Groot PGet al. Antiphospholipid syndrome. Nat Rev Dis Primers. 2018;4:18005. [PMID: 29368699]  doi: 10.1038/nrdp.2018.5
2.
Arachchillage DRJLaffan M. Pathogenesis and management of antiphospholipid syndrome. Br J Haematol. 2017;178:181-195. [PMID: 28339096]  doi: 10.1111/bjh.14632
3.
Miyakis SLockshin MDAtsumi Tet al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295-306. [PMID: 16420554]
4.
Asherson RAKhamashta MAOrdi-Ros Jet al. The “primary” antiphospholipid syndrome: major clinical and serological features. Medicine (Baltimore). 1989;68:366-74. [PMID: 2509856]
5.
Finazzi GMarchioli RBrancaccio Vet al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost. 2005;3:848-53. [PMID: 15869575]
6.
Crowther MAGinsberg JSJulian Jet al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 2003;349:1133-8. [PMID: 13679527]
7.
Ruiz-Irastorza GHunt BJKhamashta MA. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum. 2007;57:1487-95. [PMID: 18050167]
8.
Levine SRBrey RLTilley BCet alAPASS Investigators. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA. 2004;291:576-84. [PMID: 14762036]
9.
Pengo VRuffatti ALegnani Cet al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost. 2010;8:237-42. [PMID: 19874470]  doi: 10.1111/j.1538-7836.2009.03674.x
10.
Bauersachs RBerkowitz SDBrenner Bet alEINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363:2499-510. [PMID: 21128814]  doi: 10.1056/NEJMoa1007903
11.
Patel MRMahaffey KWGarg Jet alROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-91. [PMID: 21830957]  doi: 10.1056/NEJMoa1009638
12.
Dufrost VRisse JReshetnyak Tet al. Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis. Autoimmun Rev. 2018;17:1011-1021. [PMID: 30103045]  doi: 10.1016/j.autrev.2018.04.009
13.
Cohen HEfthymiou MIsenberg DA. Use of direct oral anticoagulants in antiphospholipid syndrome. J Thromb Haemost. 2018;16:1028-1039. [PMID: 29624847]  doi: 10.1111/jth.14017
14.
Malec KGóralczyk TUndas A. The use of direct oral anticoagulants in 56 patients with antiphospholipid syndrome. Thromb Res. 2017;152:93-97. [PMID: 27989533]  doi: 10.1016/j.thromres.2016.12.009
15.
Johnsen SLauvsnes MBOmdal R. Treatment failure of direct oral anticoagulants in anti-phospholipid syndrome [Letter]. Scand J Rheumatol. 2018;47:427-428. [PMID: 29297243]  doi: 10.1080/03009742.2017.1369156
16.
Joshi AHong JSiva C. Recurrent thrombosis in patients with antiphospholipid syndrome receiving newer oral anticoagulants: a case report and review of literature. Clin Med Res. 2017;15:41-44. [PMID: 28751467]  doi: 10.3121/cmr.2017.1349
17.
Win KRodgers GM. New oral anticoagulants may not be effective to prevent venous thromboembolism in patients with antiphospholipid syndrome [Letter]. Am J Hematol. 2014;89:1017. [PMID: 25043836]  doi: 10.1002/ajh.23797
18.
Dufrost VRisse JZuily Set al. Direct oral anticoagulants use in antiphospholipid syndrome: are these drugs an effective and safe alternative to warfarin? A systematic review of the literature. Curr Rheumatol Rep. 2016;18:74. [PMID: 27812956]  doi: 10.1007/s11926-016-0623-7
19.
Crowley MPCuadrado MJHunt BJ. Catastrophic antiphospholipid syndrome on switching from warfarin to rivaroxaban [Letter]. Thromb Res. 2017;153:37-39. [PMID: 28319823]  doi: 10.1016/j.thromres.2017.03.006
20.
Cohen HHunt BJEfthymiou Met alRAPS trial investigators. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial. Lancet Haematol. 2016;3:e426-36. [PMID: 27570089]  doi: 10.1016/S2352-3026(16)30079-5
21.
Pengo VDenas GZoppellaro Get al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. 2018;132:1365-1371. [PMID: 30002145]  doi: 10.1182/blood-2018-04-848333
22.
Pengo VTripodi AReber Get alSubcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2009;7:1737-40. [PMID: 19624461]  doi: 10.1111/j.1538-7836.2009.03555.x
23.
Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [Letter]. Arthritis Rheum. 1997;40:1725. [PMID: 9324032]
24.
24. Electronic Medicines Compendium. Patient leaflet. Bayer Xarelto 15- and 20-mg film-coated tablets. May 18, 2016. Accessed at www.medicines.org.uk/emc/product/8419/smpc on 19 September 2019.
25.
Schouten HJGeersing GJKoek HLet al. Diagnostic accuracy of conventional or age adjusted D-dimer cut-off values in older patients with suspected venous thromboembolism: systematic review and meta-analysis. BMJ. 2013;346:f2492. [PMID: 23645857]  doi: 10.1136/bmj.f2492
26.
Sonneveld MAde Maat MPLeebeek FW. Von Willebrand factor and ADAMTS13 in arterial thrombosis: a systematic review and meta-analysis. Blood Rev. 2014;28:167-78. [PMID: 24825749]  doi: 10.1016/j.blre.2014.04.003
27.
Fonseca AGD'Cruz DP. Controversies in the antiphospholipid syndrome: can we ever stop warfarin? J Autoimmune Dis. 2008;5:6. [PMID: 19014462]  doi: 10.1186/1740-2557-5-6
28.
Sciascia SSanna GMurru Vet al. GAPSS: the global anti-phospholipid syndrome score. Rheumatology (Oxford). 2013;52:1397-403. [PMID: 23315788]  doi: 10.1093/rheumatology/kes388
29.
Hart RGPearce LAAguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857-67. [PMID: 17577005]
30.
Matyja-Bednarczyk ASwadzba JIwaniec Tet al. Risk factors for arterial thrombosis in antiphospholipid syndrome. Thromb Res. 2014;133:173-6. [PMID: 24321419]  doi: 10.1016/j.thromres.2013.11.012
31.
Radin MSchreiber KCecchi Iet al. The risk of ischaemic stroke in primary antiphospholipid syndrome patients: a prospective study. Eur J Neurol. 2018;25:320-325. [PMID: 29082583]  doi: 10.1111/ene.13499
32.
Francès CNiang SLaffitte Eet al. Dermatologic manifestations of the antiphospholipid syndrome: two hundred consecutive cases. Arthritis Rheum. 2005;52:1785-93. [PMID: 15934071]
33.
Francès CPapo TWechsler Bet al. Sneddon syndrome with or without antiphospholipid antibodies. A comparative study in 46 patients. Medicine (Baltimore). 1999;78:209-19. [PMID: 10424203]
34.
Sneddon IB. Cerebro-vascular lesions and livedo reticularis. Br J Dermatol. 1965;77:180-5. [PMID: 14278790]
35.
Nuri ETaraborelli MAndreoli Let al. Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome. Immunol Res. 2017;65:17-24. [PMID: 27406736]  doi: 10.1007/s12026-016-8812-z
36.
Frost CSong YBarrett YCet al. A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban. Clin Pharmacol. 2014;6:179-87. [PMID: 25419161]  doi: 10.2147/CPAA.S61131
37.
Schofield JRHassell K. Dosing considerations in the use of the direct oral anticoagulants in the antiphospholipid syndrome. J Clin Pharm Ther. 2018;43:104-106. [PMID: 28656623]  doi: 10.1111/jcpt.12582
38.
Perzborn EStrassburger JWilmen Aet al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939—an oral, direct Factor Xa inhibitor. J Thromb Haemost. 2005;3:514-21. [PMID: 15748242]

Comments

0 Comments
Sign In to Submit A Comment
Stephan Moll 17 October 2019
Rivaroxaban vs VKA in APS
To the editor:
A bias may well have been introduced into the study by Ordi-Ros et al influencing the findings that more thrombotic events occurred in the rivaroxaban treated group than in the vitamin K antagonists (VKA) group, as the study may have favored enrollment of patients who tend to do well on VKAs [ref 1]. It would be important to know (a) how long patients had been on anticoagulation for their previous thrombotic event(s) before they were enrolled and (b) how many of them had previously been treated with a VKA or a direct oral anticoagulant (DOAC). Given the enrollment criteria, I suspect that the anticoagulant used prior to study enrollment had been a VKA in the majority of patients.
VKAs are known to have a substantial failure rate with recurrent thrombosis occurring in up to 11.1 % of patients [ref 2,3]. In clinical practice, such patients are often switched to another anticoagulant and would likely not have been approached for enrollment into the current study given their warfarin failure. Therefore, this study likely enrolled patients who, by their history of having tolerated a VKA well, were expected to continue to do well on a VKA. On the other hand, a number of patients randomized to the rivaroxaban arm were likely rivaroxaban-naïve, thus never before had a chance to prove rivaroxaban failure. This may have led to a bias of the observed lower thrombosis rate in the VKA compared to the rivaroxaban group. The TRAPS study, also did not report the pre-enrollment anticoagulant drug and treatment length details and, therefore, may have been biased in the same way [ref 4].
The only scientifically accurate clinical conclusion that can be drawn from the current study – as well as the TRAPS study - is this: Patients with APS and a history of thrombosis who have done well on a VKA are best continued on a VKA as they have a low VKA failure rate, but a higher rate if switched to rivaroxaban. In patients with newly diagnosed APS, however, it is currently not known whether a VKA or a DOAC is a better choice; either one can lead to anticoagulant failure. The strong statement in the Summary for Patients, that “Rivaroxaban should not be used to prevent blood clots in patients with APS”, is scientifically not solid or justifiable given the limitations discussed above [ref 5].

References
1. Ordi-Ros J, Sáez-Comet L, Pérez-Conesa M, Vidal X, Riera-Mestre A, Castro-Salomó A, Cuquet-Pedragosa J, Ortiz-Santamaria V, Mauri-Plana M, Solé C, Cortés-Hernández J. Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome: A Randomized Noninferiority Trial. Ann Intern Med. 2019 Oct 15. doi: 10.7326/M19-0291. [Epub ahead of print].
2. Crowther MA, Ginsberg JS, Julian J, Denburg J, Hirsh J, Douketis J, Laskin C, Fortin P, Anderson D, Kearon C, Clarke A, Geerts W, Forgie M, Green D, Costantini L, Yacura W, Wilson S, Gent M, Kovacs MJ. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 2003 Sep 18;349(12):1133-8.
3. Finazzi G, Marchioli R, Brancaccio V, Schinco P, Wisloff F, Musial J, Baudo F, Berrettini M, Testa S, D'Angelo A, Tognoni G, Barbui T A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost. 2005 May;3(5):848-53.
4. Pengo V, Denas G, Zoppellaro G, Jose SP, Hoxha A, Ruffatti A, Andreoli L, Tincani A, Cenci C, Prisco D, Fierro T, Gresele P, Cafolla A, De Micheli V, Ghirarduzzi A, Tosetto A, Falanga A, Martinelli I, Testa S, Barcellona D, Gerosa M, Banzato A. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. 2018 Sep 27;132(13):1365-1371. doi: 10.1182/blood-2018-04-848333. Epub 2018 Jul 12.
5. Summaries for patients. Rivaroxaban versus Vitamin K Antagonist in Antiphospholipid Syndrome. Ann Intern Med Oct 15, 2019.

Disclosures: None

Derek Leong RPh, BScPhm, ACPR, Peter E. Wu MD, MSc, FRCPC 7 November 2019
Corticosteroid drug interactions with rivaroxaban
To the editor:

We read with interest this important study by Ordi-Ros and colleagues comparing the efficacy and safety of rivaroxaban versus vitamin K antagonist (VKA) for secondary thromboprophylaxis in patients with antiphospholipid antibody syndrome (APS).(1) Surprisingly, not only was rivaroxaban shown to be not non-inferior to VKA, but there was also a nearly two-fold increase (albeit statistically non-significant) in thrombotic events (rivaroxaban, 11.6% vs. VKA, 6.3%).(1) These results were similar to the Trial on Rivaroxaban in AntiPhospholid Syndrome (TRAPS) study conducted in patients with triple-positive APS.(2) It is unclear why patients receiving rivaroxaban had a higher incidence of thrombotic events and the authors present several sensible potential explanations in their discussion. Expanding on their first hypothesis of subtherapeutic rivaroxaban drug concentrations, we would like to propose an additional potential explanation for the study findings.

Rivaroxaban is a substrate of both CYP3A4 and P-glycoprotein (P-gp) at the level of the gut, liver, and kidney.(3) While patients who were taking CYP3A4 inducers, such as rifampin, phenytoin, phenobarbital and carbamazepine were excluded from the study, 27.4% of patients in the rivaroxaban group were taking corticosteroids.(1) Similarly in the TRAPS study, 19% of patients receiving rivaroxaban were also receiving corticosteroids.(2) Corticosteroids have been demonstrated to induce CYP3A4 and P-gp which would result in reduced bioavailability, increased metabolism and excretion, and ultimately lower, potentially subtherapeutic serum concentrations that would put a patient at increased risk for thrombosis.(3-5) The European Society of Cardiology guidelines recommend avoiding concomitant use of direct oral anticoagulants (DOACs) with corticosteroids; specifically dexamethasone is contraindicated, and caution is advised with prednisone.(3) Without therapeutic drug monitoring, it is impossible to be certain of levels, but given that more than a quarter of the study participants were on corticosteroids, the consequent CYP3A4 and P-gp induction could be a real explanation as to why rivaroxaban failed in this study. All DOACs are subject to this drug interaction with corticosteroids to some degree, and future studies examining DOACs in APS should take this into account.


References:

1. Ordi-Ros J, Saez-Comet L, Perez-Conesa M, et al. Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: A randomized non-inferiority trial. Ann Intern Med. 15 October 2019. [Epub ahead of print]. doi: 10.7326/M19-0291.
2. Pengo V, Denas G, Zoppellaro G, et al. Rivaroxaban vs. warfarin in high-risk patients with antiphospholipid syndrome. Blood. 2018;132:1365-1371.
3. Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39:1330-1393.
4. Shimada T, Terada A, Yokogawa K, et al. Lowered blood concentration of tacrolimus and its recovery with changes in expression of CYP3A and P-glycoprotein after high-dose steroid therapy. Transplantation. 2002;74:1419-1424.
5. Usui T, Saitoh Y, Komada F. Induction of CYP3As in HepG2 cells by several drugs – association between induction of CYP3A4 and expression of glucocorticoid receptor. Biol Pharm Bull. 2003;26:510-517.
Josefina Cortés-Hernández, MD, PhD 26 November 2019
Authors' Response to Leong
Leong et al suggest that the greater number of recurrent thrombosis in patients in the rivaroxaban treatment group compared to patients treated with VKA may be a consequence of the interference of some drugs on the metabolism of rivaroxaban such as corticosteroids. It is true that in patients with systemic lupus erythematosus (SLE) the use of corticosteroids is common. However, in patients with primary APS, prednisone treatment is rare. High doses of prednisone (>0.5 mg/kg) or even i.v methylprednisolone pulses can be administered in patients with severe complications such as pulmonary capillaritis, catastrophic syndrome, severe thrombopenia or hemolytic anemia. Although corticoids are commonly used in patients with SLE, in our study only 32.6% of the rivaroxaban-treated patients and 28.4% of VKA-treated group were taking prednisone at inclusion (Table 1 of the original paper) at a low dose (mean dose of 2.68±6.5 mg/day in the rivaroxaban group and 1.89±5.29 mg/day in the VKA group) (1). During the study period, 8 SLE patients in the rivaroxaban group had a systemic flare that required an increased dose of corticosteroids. Two of them had a severe flare requiring pulses of methyprednisolone. None of them had a recurrent thrombosis. Of the 3 SLE flares occurring in the VKA group, only one received pulses of methylprednisolone for a severe membranous lupus glomerulonephritis and also developed a DVT. This episode was more related to the coexisting nephrotic syndrome than to the corticosteroid doses.
Drug, herbal medicines and foods have many interactions with old and new oral anticoagulants (2). The DOACS are approved for the prevention and treatment of venous thromboembolism and of systemic and cerebral embolism in atrial fibrillation. Their advantages over VKA include a more predictable and stable anticoagulant effect and fewer interactions with foods, herbal supplements or drugs. However, the interactions have been poorly evaluated to date and more studies are needed in order to understand these aspects better. Awareness of drugs that alter the function of the P-gp efflux transporter protein and CYP3A4 enzymes and provide additive effects should enable prescribers to anticipate and avoid potential drug-drug interactions involving the new oral anticoagulants [3]. In new prospective randomized studies, it is important to consider possible pharmacological interactions of DOACs and other drugs that patients receive.

References
1. Ordi-Ros J, Sáez-Comet L, Pérez-Conesa M, Vidal X, Riera-Mestre A, Castro-Salomó A, Cuquet-Pedragosa J, Ortiz-Santamaria V, Mauri-Plana M, Solé C, Cortés-Hernández J. Rivaroxaban versus Vitamin K antagonist in Antiphospholipid síndrome: a randomized Noninferiority Trial. Ann Intern Med 2019 Oc 15.doi: 10.7326/M19-0291 [Epub ahead of print]
2.- Di Minno A, Frigerio B, Spadarella G, Ravani A, Sansaro D, Amato M, Kitzmiller JP, Pepi M, Tremoli E, Baldassarre D. Old and oral anticoagulants: Food, herbal medicines and drug interactions. Blood Reviews 2017;31:193-203
3.- Herink MC, Zhuo YF, Williams CD, DeLoughery TG. Clinical Management of Pharmacokinetic Drug Interactions with Direct Oral Anticoagulants (DOACs). Drugs 2019;79:1625-1634.
Josefina Cortés-Hernández, MD, PhD 26 November 2019
Authors Response to Moll
We appreciate Stephan Moll for his comments and concerns about the bias that may have been introduced in our study, Rivaroxaban Versus Vitamin K Antagonist (VKA) in Antiphospholipid Syndrome (APS): A randomized noninferiority trial, favouring the enrolment of APS patients who tend to do well on VKAs [1]. We welcome the opportunity to clarify our results.
At the time of APS diagnosis, all patients were anticoagulated with VKA, standard INR 2.0 to 3.0. Those patients with recurrent arterial or venous thrombosis despite therapy were treated according standard clinical practice increasing the INR target to 3-4 or adding low dose aspirin (100 mg/day) rather than changing to direct oral anticoagulants (DOAC) [2]. DOACS were not financed by health authorities at the time of the study in APS. Thrombosis recurrence in APS occurs in up to 11.1 % of patients while treated with VKA [ref 3,4]. In response to treatment history, the duration of anticoagulation ranged between 4 to 15 years and there were no differences between VKA and Rivaroxaban groups regarding the period of exposure to VKA prior to enrolment. Median time on VKA in the rivaroxaban-treated group was 7 years (4-15 years) and 6 years (4-12) for the VKA-treated group [1].
In our study, not only patients doing well on VKA were enrolled, but there were also 28 APS patients (14.7%) with a history of recurrent thrombosis despite VKA that at inclusion were requiring high intensity anticoagulation (INR 3.1 to 4.0). As shown in Table 1 [1], the proportion of patients enrolled with a higher target INR (3.1 to 4.0) was similar in both groups (12/95 (12.6%) rivaroxaban vs 16/95 (16.8%) VKA) [1]. Therefore, since there was no selection at inclusion of patients based on their response to VKA, the introduction of a bias is unlikely. Finally, we agree that there is not enough knowledge for comparative VKA and DOAC rates of failure in newly diagnosed APS patients. However, new patients should be evaluated individually and stratified according to their thrombotic risk. Rivaroxaban should not be used in patients with APS with triple aPL positivity and caution needs to be taken with those with migraine, valvulopathy and livedo reticularis [1,5].
References:
1. Ordi-Ros J, Sáez-Comet L, Pérez-Conesa M, Vidal X, Riera-Mestre A, Castro-Salomó A, Cuquet-Pedragosa J, Ortiz-Santamaria V, Mauri-Plana M, Solé C, Cortés-Hernández J. Rivaroxaban versus Vitamin K antagonist in Antiphospholipid síndrome: a randomized Noninferiority Trial. Ann Intern Med 2019 Oc 15.doi: 10.7326/M19-0291 [Epub ahead of print]
2. Tektonidou MG, Andreoli L, Limper M, Amoura Z, Cervera R, Costedoat-Chalumeau N, Cuadrado MJ, Dörner T, Ferrer-Oliveras R, Hambly K, Khamashta MA, King J, Marchiori F, Meroni PL, Mosca M, Pengo V, Raio L, Ruiz-Irastorza G, Shoenfeld Y, Stojanovich L, Svenungsson E, Wahl D, Tincani A, Ward MM. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019 Oct;78(10):1296-1304. doi: 10.1136/annrheumdis-2019-215213.
3. Crowther MA, Ginsberg JS, Julian J, Denburg J, Hirsh J, Douketis J, Laskin C, Fortin P, Anderson D, Kearon C, Clarke A, Geerts W, Forgie M, Green D, Costantini L, Yacura W, Wilson S, Gent M, Kovacs MJ. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 2003 Sep 18;349(12):1133-8.
4. Finazzi G, Marchioli R, Brancaccio V, Schinco P, Wisloff F, Musial J, Baudo F, Berrettini M, Testa S, D'Angelo A, Tognoni G, Barbui T. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost. 2005 May;3(5):848-53.
5. Pengo V, Denas G, Zoppellaro G, Jose SP, Hoxha A, Ruffatti A, Andreoli L, Tincani A, Cenci C, Prisco D, Fierro T, Gresele P, Cafolla A, De Micheli V, Ghirarduzzi A, Tosetto A, Falanga A, Martinelli I, Testa S, Barcellona D, Gerosa M, Banzato A. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. 2018 Sep 27;132(13):1365-1371. doi: 10.1182/blood-2018-04-848333. Epub 2018 Jul 12.
Cortes-Hernandez J, MD, PhD 17 January 2020
Authors' Response
Regarding Stephan Moll’s concerns about a possible bias by favouring enrolment of patients doing well on VKAs, we would like to clarify there was no patient selection at enrolment based on their response to VKA. In addition to stable VKA recipients, there were 28 APS patients (14.7%) with historical recurrent thrombosis despite VKA, receiving high intensity anticoagulation (INR 3.1 to 4.0). After randomization, the distribution in both cohorts was similar (12/95 (12.6%) rivaroxaban vs 16/95 (16.8%) VKA) [1].
All patients were anticoagulated with an adjusted-dose of VKA since diagnosis. No one received DOACS as they were not financed by health authorities for APS at study time. Duration of VKA anticoagulation prior to enrolment ranged between 4 to 15 years and there was no significant difference between groups. Median time on VKA in the rivaroxaban-treated group was 7 years (4-15 years) and 6 years (4-12) for the VKA-treated group [1]. Finally, we agree that there is not enough knowledge for comparative VKA and DOAC failure rates in newly-diagnosed APS. However, new patients should be evaluated individually and stratified according to their thrombotic risk. Rivaroxaban should not be indicated in APS patients with triple aPL positivity. Caution needs to be taken in those with migraine, valvulopathy and livedo reticularis racemosa [1,2].
Leong et al suggest a possible drug interaction, such as corticosteroids, on the rivaroxaban metabolism as a cause of the observed increased thrombosis. Corticosteroid treatment in APS is rarer than in systemic lupus erythematosus (SLE), although high prednisone doses (>0.5 mg/kg or i.v methylprednisolone pulses) are administered in severe APS complications (e.g pulmonary capillaritis, catastrophic syndrome, severe thrombocytopenia or hemolytic anemia). The influence of steroids in our results seems unlikely since only 32.6% of the rivaroxaban-treated patients and 28.4% of VKA-treated group were receiving prednisone at low doses (mean dose of 2.68±6.5 mg/day and 1.89±5.29 mg/day respectively) (1). SLE flares requiring a steroid increment only occurred in 8 patients in the rivaroxaban group and 3 in the VKA group. Only one in the VKA group with severe membranous lupus glomerulonephritis developed a DVT.
Drugs, herbal medicines and foods have many interactions with old and new oral anticoagulants [3]. The advantages of DOACS over VKA include a more predictable and stable anticoagulant effect and fewer interactions but these have not been extensively studied. Awareness of drugs interacting with the P-gp efflux transporter protein and CYP3A4 enzymes should flag potential drug-drug interactions with new oral anticoagulants [4]. Pharmacological interactions with DOACS should be considered in future studies.

References:
1. Ordi-Ros J, Sáez-Comet L, Pérez-Conesa M, Vidal X, Riera-Mestre A, Castro-Salomó A, Cuquet-Pedragosa J, Ortiz-Santamaria V, Mauri-Plana M, Solé C, Cortés-Hernández J. Rivaroxaban versus Vitamin K antagonist in Antiphospholipid síndrome: a randomized Noninferiority Trial. Ann Intern Med 2019 Oc 15.doi: 10.7326/M19-0291 [Epub ahead of print]
2. Pengo V, Denas G, Zoppellaro G, Jose SP, Hoxha A, Ruffatti A, Andreoli L, Tincani A, Cenci C, Prisco D, Fierro T, Gresele P, Cafolla A, De Micheli V, Ghirarduzzi A, Tosetto A, Falanga A, Martinelli I, Testa S, Barcellona D, Gerosa M, Banzato A. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. 2018 Sep 27;132(13):1365-1371. doi: 10.1182/blood-2018-04-848333. Epub 2018 Jul 12.
3. Di Minno A, Frigerio B, Spadarella G, Ravani A, Sansaro D, Amato M, Kitzmiller JP, Pepi M, Tremoli E, Baldassarre D. Old and oral anticoagulants: Food, herbal medicines and drug interactions. Blood Reviews 2017;31:193-203
4. Herink MC, Zhuo YF, Williams CD, DeLoughery TG. Clinical Management of Pharmacokinetic Drug Interactions with Direct Oral Anticoagulants (DOACs). Drugs 2019;79:1625-1634.

Information & Authors

Information

Published In

cover image Annals of Internal Medicine
Annals of Internal Medicine
Volume 171Number 1019 November 2019
Pages: 685 - 694

History

Published online: 15 October 2019
Published in issue: 19 November 2019

Keywords

Authors

Affiliations

Josep Ordi-Ros, MD, PhD
Vall d'Hebrón Research Institute, Barcelona, Spain (J.O., X.V., C.S., J.C.)
Luis Sáez-Comet, MD, PhD
Miguel Servet Hospital, Zaragoza, Spain (L.S., M.P.)
Mercedes Pérez-Conesa, MD
Miguel Servet Hospital, Zaragoza, Spain (L.S., M.P.)
Xavier Vidal, MD, PhD
Vall d'Hebrón Research Institute, Barcelona, Spain (J.O., X.V., C.S., J.C.)
Antoni Riera-Mestre, MD, PhD
Bellvitge University Hospital-IDIBELL, Barcelona, Spain (A.R.)
Antoni Castro-Salomó, MD, PhD
Sant Joan de Reus University Hospital, Reus, Spain (A.C.)
Jordi Cuquet-Pedragosa, MD
Granollers University Hospital, Granollers, Spain (J.C., V.O.)
Vera Ortiz-Santamaria, MD
Granollers University Hospital, Granollers, Spain (J.C., V.O.)
Montserrat Mauri-Plana, MD, PhD
Mataró Hospital, Mataró, Spain (M.M.)
Cristina Solé, PhD
Vall d'Hebrón Research Institute, Barcelona, Spain (J.O., X.V., C.S., J.C.)
Josefina Cortés-Hernández, MD, PhD
Vall d'Hebrón Research Institute, Barcelona, Spain (J.O., X.V., C.S., J.C.)
Note: The corresponding author had full access to all data and final responsibility for the decision to submit the manuscript for publication.
Acknowledgment: The authors thank the Catalan Lupus Foundation and all the patients who participated in the trial; the investigators who recruited patients to the study; and the research staff who assisted with patient recruitment, data collection, biomarker measurements, and data management.
Financial Support: From Bayer Hispania.
Disclosures: Drs. Ordi-Ros and Cortés-Hernández report institutional support from Bayer Hispania to conduct the study. Dr. Ortiz-Santamaria reports personal fees and nonfinancial support from Pfizer, Janssen, Lilly, GSK, Novartis, Roche, and Abbott outside the submitted work. Authors not named here have disclosed no conflicts of interest. Disclosures can also be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M19-0291.
Editors' Disclosures: Christine Laine, MD, MPH, Editor in Chief, reports that her spouse has stock options/holdings with Targeted Diagnostics and Therapeutics. Darren B. Taichman, MD, PhD, Executive Editor, reports that he has no financial relationships or interests to disclose. Cynthia D. Mulrow, MD, MSc, Senior Deputy Editor, reports that she has no relationships or interests to disclose. Jaya K. Rao, MD, MHS, Deputy Editor, reports that she has stock holdings/options in Eli Lilly and Pfizer. Catharine B. Stack, PhD, MS, Deputy Editor, Statistics, reports that she has stock holdings in Pfizer, Johnson & Johnson, and Colgate-Palmolive. Christina C. Wee, MD, MPH, Deputy Editor, reports employment with Beth Israel Deaconess Medical Center. Sankey V. Williams, MD, Deputy Editor, reports that he has no financial relationships or interests to disclose. Yu-Xiao Yang, MD, MSCE, Deputy Editor, reports that he has no financial relationships or interest to disclose.
Data Sharing Statement: The following data will be made available with publication: deidentified participant data (available from Dr. Josefina Cortés-Hernández; e-mail, [email protected]). The following supporting documents will be made available with publication: informed consent form (available from Dr. Josefina Cortés-Hernández; e-mail, [email protected]). These data will be made available to researchers whose proposed use of the data has been approved for a specified purpose, with investigator support, and with a signed data access agreement (no restrictions).
Corresponding Author: Josefina Cortés-Hernández, MD, PhD, Department of Internal Medicine, Rheumatology Research Group, Vall d'Hebrón University Hospital Research Institute, Passeig Vall d'Hebrón 119-129, 08035, Barcelona, Spain; e-mail, [email protected].
Current Author Addresses: Drs. Ordi-Ros, Vidal, and Solé: Vall d'Hebrón University Hospital Research Institute, Passeig Vall d'Hebrón 119-129, 08035, Barcelona, Spain.
Drs. Sáez-Comet and Pérez-Conesa: Servicio de Medicina Interna, Hospital Universitario Miguel Servet, Paseo Isabel La Católica 9, 50009, Zaragoza, Spain.
Dr. Riera-Mestre: Internal Medicine Department, L'Hospitalet de Llobrega, Feixa llarga s/n, 08907, Barcelona, Spain.
Dr. Castro-Salomó: Internal Medicine Department, Sant Joan de Reus University Hospital, Sant Joaquim 42 1-3, 43204, Reus, Spain.
Drs. Cuquet-Pedragosa and Ortiz-Sanatmaria: Granollers University Hospital, Avinguda Francesc Ribas s/n, 08402, Granollers, Spain.
Dr. Mauri-Plana: Department of Internal Medicine, Mataro Hospital, Carrer de Cirera, 230, 08304, Mataró, Spain.
Dr. Cortés-Hernández: Department of Internal Medicine, Rheumatology Research Group, Vall d'Hebrón University Hospital Research Institute, Passeig Vall d'Hebrón 119-129, 08035, Barcelona, Spain.
Author Contributions: Conception and design: J. Ordi-Ros, M. Pérez-Conesa, X. Vidal, J. Cortés-Hernández.
Analysis and interpretation of the data: J. Ordi-Ros, X. Vidal, A. Castro-Salomó, C. Solé, J. Cortés-Hernández.
Drafting of the article: J. Ordi-Ros, L. Sáez-Comet, X. Vidal, A. Riera-Mestre, C. Solé, J. Cortés-Hernández.
Critical revision for important intellectual content: J. Ordi-Ros, L. Sáez-Comet, X. Vidal, A. Castro-Salomó, J. Cuquet-Pedragosa, C. Solé, J. Cortés-Hernández.
Final approval of the article: J. Ordi-Ros, L. Sáez-Comet, M. Pérez-Conesa, X. Vidal, A. Riera-Mestre, A. Castro-Salomó, J. Cuquet-Pedragosa, V. Ortiz-Santamaria, M. Mauri-Plana, C. Solé, J. Cortés-Hernández.
Provision of study materials or patients: J. Ordi-Ros, L. Sáez-Comet, M. Pérez-Conesa, A. Castro-Salomó, V. Ortiz-Santamaria, J. Cortés-Hernández.
Statistical expertise: X. Vidal.
Obtaining of funding: J. Ordi-Ros, J. Cortés-Hernández.
Administrative, technical, or logistic support: J. Ordi-Ros, L. Sáez-Comet, J. Cortés-Hernández.
Collection and assembly of data: J. Ordi-Ros, L. Sáez-Comet, M. Pérez-Conesa, X. Vidal, A. Riera-Mestre, A. Castro-Salomó, J. Cuquet-Pedragosa, M. Mauri-Plana, J. Cortés-Hernández.
This article was published at Annals.org on 15 October 2019.

Metrics & Citations

Metrics

Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. For an editable text file, please select Medlars format which will download as a .txt file. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format





Download article citation data for:
Josep Ordi-Ros, Luis Sáez-Comet, Mercedes Pérez-Conesa, et al. Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome: A Randomized Noninferiority Trial. Ann Intern Med.2019;171:685-694. [Epub 15 October 2019]. doi:10.7326/M19-0291

View More

Login Options:
Purchase

You will be redirected to acponline.org to sign-in to Annals to complete your purchase.

Access to EPUBs and PDFs for FREE Annals content requires users to be registered and logged in. A subscription is not required. You can create a free account below or from the following link. You will be redirected to acponline.org to create an account that will provide access to Annals. If you are accessing the Free Annals content via your institution's access, registration is not required.

Create your Free Account

You will be redirected to acponline.org to create an account that will provide access to Annals.

View options

PDF/EPUB

View PDF/EPUB

Related in ACP Journals

Full Text

View Full Text

Media

Figures

Other

Tables

Share

Share

Copy the content Link

Share on social media